An efficient, versatile linker is developed for the synthesis of C-terminal primary/secondary amides and hydrazides as well as peptide alcohols, which is compatible with solid-phase peptide synthesis (SPPS) and suppresses side reactions. It is termed as Ramage Linker.
The basis for the Ramage linker is a dibenzocyclohepta-1,3-dienyl system with an additional oxygen substituent which serves on one hand for further stabilization. The Ramage linker represents an alternative to the commonly used Rinklinker for the synthesis of C-terminal peptide amides. The three-circular structure of the Ramage linker prevents its fragmentation cleavage from the resin followed by back alkylation. This is a drawback commonly observed during peptide synthesis with the Rinklinker. Consequently, the Ramage linker delivers peptides in higher purity with less impurities compared to peptides produced with the Rinklinker.
Besides C-terminal amides, the Ramage linker can also be used for the synthesis of C-terminal peptide alcohols.
Their diverse biological activities and clinical importance are described in various publications. One prominent example is Octreotide, a metabolically stable analog of somatostatin which contains threoninol at the C-terminus. Starting from the Ramage linker or resin, the deprotected primary amine can be converted to a hydroxy moiety and further to the corresponding chloride, which can then be loaded with Fmoc-amino alcohols. Analogous to the preparation of peptide amides, the synthesized sequence can be detached from the linker and fully deprotected by conventional reagents.
References:
- Design of a versatile linker for solid phase peptide synthesis: Synthesis of C-terminal primary / secondary amides and hydrazides; R. Ramage, S. L. Irving and C. McInnes; Tetrahedron Lett 1993; 34: 6599-6602
- Functionalized Resins for the Synthesis of Peptide Alcohols; F. J. Ferrer Gago, L. Q. Koh, D. P. Lane; Chem. Eur. J. 2020; 26(2): 379-383
In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.
The global pharmaceutical fine chemicals sector is undergoing a profound transformation, with India emerging as a central growth engine amid sweeping changes in supply chain strategies and regulatory priorities. As drug makers and contract manufacturers adapt to stricter oversight and evolving sourcing preferences, the industry’s focus is shifting rapidly from cost efficiency to compliance, localisation and technical sophistication.
Stakeholders are being encouraged to weigh in on the European Chemicals Agency (ECHA) 60-day public consultation period related to a planned ban on per-and-polyfluoroalkyl (PFAS) substances, also known as forever chemicals.
We’re pleased to share an important milestone in our sustainability journey.
ExSyn has been awarded the EcoVadis Platinum Medal, placing us among the top 1% of companies globally evaluated for environmental, social and ethical performance.
While fears around a complete shutdown of the Strait of Hormuz primarily raise concerns around oil prices and energy security, recent history shows that even partial disruptions or security threats along key sea routes can quickly spill over into freight inflation, longer transit times and working capital stress for exporters and importers.
The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to zero.
As we approach the close of this year, we at ExSyn would like to extend our heartfelt gratitude for your trust, collaboration, and continued support. Your confidence in our products and services has been the driving force behind our growth and success.
The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases.
Products containing titanium dioxide in the EU are no longer required to carry warnings about cancer risk, after the European Chemicals Agency (Echa) revoked its classification as a suspected carcinogen. The move follows a June 2025 decision by the Court of Justice of the European Union and means that safety data sheets, labelling and packaging requirements for titanium dioxide have been relaxed across industries including paints, pharmaceuticals, cosmetics and food.